An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

Journal article

We treated 13 patients with progressive MS with mitoxantrone. All patients received a standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with dosage adjustments depending on the hematologic profile at the nadir. The treatment was well tolerated, with the most common side effect being mild nausea. Four of seven women developed transient secondary amenorrhea. The postenrollment clinical behavior of these patients was generally more favorable than during the...

Expand abstract

Authors: Noseworthy, J; Hopkins, M; Vandervoort, M; Karlik, S; Lee, D

• Publication status: Published
• Journal: Neurology
• Volume: 43
• Issue: 7
• Pages: 1401-1406
• Publication date: 1993-07-01
• DOI: 10.1212/wnl.43.7.1401
• EISSN: 1526-632X
• ISSN: 0028-3878
• Language: English
• Keywords: Humans; Pilot Projects; Adult; Middle Aged; Mitoxantrone; Female; Male; Multiple Sclerosis; Magnetic Resonance Imaging; Brain